^
Association details:
Biomarker:No biomarker
Cancer:Colon Cancer
Drug:irinotecan (Topoisomerase I inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
01/30/2020
Excerpt:
CAMPTOSAR is a topoisomerase inhibitor indicated for...Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.